Log In
BCIQ
Print this Print this
 

Cytomegalovirus (CMV) vaccine (ASP0113, VCL-CB01) (formerly TransVax)

  Manage Alerts
Collapse Summary General Information
Company Vical Inc.
DescriptionDNA vaccine carrying phosphoprotein 65 and glycoprotein B formulated with poloxamer
Molecular Target Human cytomegalovirus (CMV) phosphoprotein 65 (pp65) (UL83) ; Human cytomegalovirus (CMV) glycoprotein B
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: DNA vaccine
Latest Stage of DevelopmentPhase III
Standard IndicationCytomegalovirus (CMV)
Indication DetailsPrevent cytomegalovirus (CMV) reactivation in CMV-seropositive hematopoietic stem cell transplant recipients; Prevent cytomegalovirus (CMV) reactivation in immunosuppressed CMV-seropositive hematopoietic stem cell transplant recipients; Prevent cytomegalovirus (CMV) reactivation in solid organ transplant recipients; Prevent cytomegalovirus reactivation in hematopoietic cell transplant recipients
Regulatory Designation
PartnerAstellas Pharma Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$130.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/14/2011

$130.0M

Undisclosed

Undisclosed

Get a free BioCentury trial today